PCN Insights, News, Videos, and More

Post-acute sequelae of COVID-19, commonly referred to as long COVID symptoms, are associated with reduced levels of the neurotransmitter serotonin, according to study findings published in the journal Cell.

Assessing odor sensitivity could provide an early indicator of impending cognitive impairment, according to recent study findings published in the journal Neurology.

A diagnosis of attention-deficit/hyperactivity disorder (ADHD) is just as likely to persist in the youngest students in a class as it is in their older classmates, according to study findings published in The Lancet Psychiatry.

Hypersomnolence, insomnia, and sleep dissatisfaction predicted the recurrence of MDD over 3 years, according to a poster presentation at Psych Congress.

With drug overdose deaths continuing to climb, Sana Symposium presenter Christopher Nicholas, PhD, said studies suggest that incorporating the use of psychedelics into treatment modalities could improve outcomes.

Andrew Penn, RN, PMHNP, and Charles Raison, MD, shared findings from late-stage trials for MDMA-assisted therapy to treat post-traumatic stress disorder and the use of psilocybin for treatment-resistant depression and major depressive...

The FDA has recently addressed the growing interest in compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders and warns clinicians considering their use.